Announced
Completed
Synopsis
Insmed, a global biopharmaceutical company, completed the acquisition of Motus Biosciences, a developer of tools intended for the development of next-generation gene therapies, for $288m.
Principals
Show Details & Financials
Sort
Search a database of more than 250,000 verified dealmakers
Receive automated updates on global transactions
Follow the activity, relationships and transactions of top dealmakers
© COPYRIGHT 2024 MERGERLINKS LIMITED.
ALL RIGHTS RESERVED.
15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.